| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| BML Investment Partners, L.P. | 8.5% | +11% | $4,335,508 | +$470,890 | 4,090,102 | +12% | Leonard Braden Michael | 16 Jun 2025 |
| BIOTECHNOLOGY VALUE FUND L P | 8.3% | $4,246,958 | 4,006,564 | BVF PARTNERS L P/IL | 31 Dec 2024 | |||
| GILEAD SCIENCES, INC. | 3.6% | $1,612,591 | 1,521,312 | GILEAD SCIENCES INC | 31 Dec 2024 | |||
| ORBIMED ADVISORS LLC | 6.9% | -58% | $820,179 | -$7,669,269 | 773,754 | -90% | ORBIMED ADVISORS LLC | 25 Jul 2025 |
As of 30 Sep 2025, 0 institutional investors reported holding 0 shares of Ikena Oncology, Inc. - Common Stock, $0.001 par value (IKNA). This represents 0% of the company’s total 11,181,416 outstanding shares.
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q3 | 0 | $0 | -$42,557,663 | $1.43 | 0 |
| 2025 Q2 | 31,761,826 | $42,558,064 | -$1,719,668 | $1.34 | 41 |
| 2025 Q1 | 32,747,670 | $41,911,271 | +$1,300,847 | $1.28 | 46 |
| 2024 Q4 | 31,710,905 | $52,000,995 | +$1,135,340 | $1.64 | 53 |
| 2024 Q3 | 28,407,567 | $49,141,929 | -$989,639 | $1.73 | 57 |
| 2024 Q2 | 29,008,151 | $47,862,655 | -$1,770,172 | $1.65 | 69 |
| 2024 Q1 | 30,097,815 | $42,738,138 | -$4,428,963 | $1.42 | 56 |
| 2023 Q4 | 0 | $0 | -$48,392 | $1.43 | 0 |
| 2023 Q3 | 32,711,624 | $141,562,227 | +$6,440,221 | $4.33 | 58 |
| 2023 Q2 | 31,199,169 | $204,665,259 | +$41,687,098 | $6.56 | 52 |
| 2023 Q1 | 24,983,174 | $86,191,879 | -$4,246,851 | $3.45 | 38 |
| 2022 Q4 | 26,264,313 | $69,861,906 | -$1,368,220 | $2.66 | 34 |
| 2022 Q3 | 26,218,089 | $93,072,465 | -$2,494,548 | $3.55 | 37 |
| 2022 Q2 | 26,692,274 | $118,249,000 | -$3,052,708 | $4.43 | 39 |
| 2022 Q1 | 27,400,848 | $167,234,122 | -$5,437,733 | $6.10 | 45 |
| 2021 Q4 | 27,300,271 | $342,431,318 | +$20,438,169 | $12.54 | 45 |
| 2021 Q3 | 20,880,074 | $271,798,000 | -$3,145,383 | $12.62 | 39 |
| 2021 Q2 | 21,064,655 | $293,192,000 | +$21,244,514 | $14.04 | 41 |
| 2021 Q1 | 19,313,430 | $538,519,000 | +$538,519,180 | $28.25 | 27 |